Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039429 · ClinicalTrials.gov registry record · Phase 2
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00039429 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 180 participants.
The verdict
NCT00039429, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally recurrent or metastatic kidney cancer.
Interventions
- DRUG atrasentan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039429
The ClinicalTrials.gov registry entry for NCT00039429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which atrasentan hydrochloride is the first listed.
NCT00039429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039429 about?
NCT00039429 is a clinical study titled "Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally recurrent or metastatic kidney cancer.
What is the current status of trial NCT00039429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2003-07-14.
What interventions are being tested in trial NCT00039429?
The interventions under investigation include: atrasentan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00039429?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.